TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR

Stock News04-21

TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver mechanism for endocrine resistance in HR+ breast cancer and its clinical translational significance. Through continuous drug screening and co-culture models, the research found that both treatment-induced and microenvironment-driven resistance converge on the co-activation of FGFR and JAK signaling pathways. This co-activation subsequently suppresses the expression of luminal-related genes, including ESR1 and PGR. Tiengotinib, an inhibitor capable of simultaneously targeting both FGFR and JAK, was shown to restore the luminal characteristics of tumor cells. Furthermore, it resensitized resistant models to endocrine therapy both in vitro and in vivo. These findings support dual FGFR-JAK blockade as an effective strategy to overcome lineage plasticity-driven endocrine resistance. A Phase II clinical trial evaluating tiengotinib in combination with endocrine therapy for advanced HR+ breast cancer is currently underway.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121493501?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121493501","market":"us","top_or_hot":-1,"title":"TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR","media":"Stock News","content":"<p>TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver mechanism for endocrine resistance in HR+ breast cancer and its clinical translational significance. Through continuous drug screening and co-culture models, the research found that both treatment-induced and microenvironment-driven resistance converge on the co-activation of FGFR and JAK signaling pathways. This co-activation subsequently suppresses the expression of luminal-related genes, including ESR1 and PGR. Tiengotinib, an inhibitor capable of simultaneously targeting both FGFR and JAK, was shown to restore the luminal characteristics of tumor cells. Furthermore, it resensitized resistant models to endocrine therapy both in vitro and in vivo. These findings support dual FGFR-JAK blockade as an effective strategy to overcome lineage plasticity-driven endocrine resistance. A Phase II clinical trial evaluating tiengotinib in combination with endocrine therapy for advanced HR+ breast cancer is currently underway.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-21 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver mechanism for endocrine resistance in HR+ breast cancer and its clinical translational significance. Through continuous drug screening and co-culture models, the research found that both treatment-induced and microenvironment-driven resistance converge on the co-activation of FGFR and JAK signaling pathways. This co-activation subsequently suppresses the expression of luminal-related genes, including ESR1 and PGR. Tiengotinib, an inhibitor capable of simultaneously targeting both FGFR and JAK, was shown to restore the luminal characteristics of tumor cells. Furthermore, it resensitized resistant models to endocrine therapy both in vitro and in vivo. These findings support dual FGFR-JAK blockade as an effective strategy to overcome lineage plasticity-driven endocrine resistance. A Phase II clinical trial evaluating tiengotinib in combination with endocrine therapy for advanced HR+ breast cancer is currently underway.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1121493501","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121493501","pubTimestamp":1776730218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK4203":"医疗保健房地产投资信托","HR":"医疗保健房地产信托","02617":"药捷安康-B","BK4225":"医疗保健房地产信托"},"translate_title":"TRANSTHERA-B（02617）在2026年AACR上展示了作为HR+乳腺癌内分泌治疗耐药机制的谱系可塑性以及Tiengotinib的临床前数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"HR":1},"content_text":"TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver mechanism for endocrine resistance in HR+ breast cancer and its clinical translational significance. Through continuous drug screening and co-culture models, the research found that both treatment-induced and microenvironment-driven resistance converge on the co-activation of FGFR and JAK signaling pathways. This co-activation subsequently suppresses the expression of luminal-related genes, including ESR1 and PGR. Tiengotinib, an inhibitor capable of simultaneously targeting both FGFR and JAK, was shown to restore the luminal characteristics of tumor cells. Furthermore, it resensitized resistant models to endocrine therapy both in vitro and in vivo. These findings support dual FGFR-JAK blockade as an effective strategy to overcome lineage plasticity-driven endocrine resistance. A Phase II clinical trial evaluating tiengotinib in combination with endocrine therapy for advanced HR+ breast cancer is currently underway.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121493501","isCrawlerRequest":true}